Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.36 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.33 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21474623 | 0.90 | MAPT (0.36) | LMNAKCNK3MAPTALDH1A1AVPR2 | |
| SCHEMBL21474621 | 0.82 | GAA (0.44) | LMNAMAPTALDH1A1AVPR2AVPR1A | |
| SCHEMBL21471605 | 0.82 | SCD (0.31) | KCNK3ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL21471611 | 0.80 | AVPR2 (0.38) | LMNAMAPTALDH1A1AVPR2AVPR1A | |
| SCHEMBL21471613 | 0.78 | NOTUM (0.32) | LMNAALDH1A1HTTSMN1; SMN2HPGD | |
| SCHEMBL20619531 | 0.77 | ALDH1A1 (0.48) | LMNAMAPTALDH1A1THRBGAA | |
| SCHEMBL20619667 | 0.76 | AVPR2 (0.38) | LMNAMAPTALDH1A1THRBAVPR2 | |
| SCHEMBL20622168 | 0.76 | AVPR2 (0.41) | LMNAMAPTAVPR2AVPR1AGAA | |
| SCHEMBL21471679 | 0.73 | AVPR2 (0.35) | LMNAMAPTALDH1A1AVPR2AVPR1A | |
| SCHEMBL20620045 | 0.72 | HDAC1 (0.42) | LMNAMAPTALDH1A1THRBAVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975094-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20190315766-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975094-B2 | Heterocyclic compounds as RSV inhibitors | SIRT1, FURIN, SIRT5 | LMNA 2849/4885KCNK3 4222/4885MAPT 3526/4885 |
| US-20190315766-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | SIRT1, FURIN, SIRT5 | LMNA 2849/4885KCNK3 4222/4885MAPT 3526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.